Paragon Bioservices Announces Management Team Additions

BALTIMORE, Jan. 26, 2015 /PRNewswire/ -- Paragon Bioservices, Inc., a contract research and GMP manufacturing organization with a focus on the development and manufacturing of biopharmaceuticals, today has announced the expansion of the company's executive team.  The new management additions follow the Company's October 2014 financing, which was led by NewSpring Capital and Camden Partners.

Paragon Bioservices Inc. Logo
According to Marco A. Chacon, CEO of Paragon, "These individuals bring years of scientific and management experience across the pharmaceutical, biotechnology and government sectors.  We are very fortunate to benefit from the depth of their diverse experience."

Mike Billard, Vice President of Project Management, joins Paragon from Royal DSMa global science-based company active in health, nutrition and materialswhere he led a North American team of project managers.  He brings over 15 years of leadership, project management and product development experience to Paragon.  His prior experience was managing regional and global cross-functional teams while a project manager at Martek Biosciences, MedImmune and Baxter Healthcare Corporation.  Mike served as an officer in the US Army and received his M.S. in Biotechnology from The Johns Hopkins University.

George Buchman, Ph.D., who joined the Company in March 2014, was recently promoted to Vice President of Preclinical Services and Process Development. George brings over 25 years of scientific and management experience to Paragon.  He joined Paragon from Chesapeake PERL, where he was CSO and Vice President of Operations.  He has also held senior level positions with Life Technologies and Celera Genomics. George received his Ph.D. in Biochemistry from the University of Maryland, College Park.

Maryanne Foy, Vice President of Human Resources & Corporate Administration, also joined Paragon from Royal DSM where she was the VP, Human Resources North America.  Maryanne has over 25 years of experience in both the biotechnology and hi-tech industries. Prior to joining DSM, she served as Senior Vice President of Aether Systems.  Maryanne's strength is in organizational change and in establishing effective manager and employee development programs.  She has an MBA in Organizational Behavior and Industrial Psychology from The Pennsylvania State University.

Anne Shiflett, Vice President of Finance, has over 20 years of managerial, financial and accounting experience.  Anne has expertise in leading the start-up and rapid growth of new and emerging companies.  She has been in the life science industry for the past nine yearsmost recently as VP, Finance at Corridor Pharmaceuticals and Alba Therapeutics.  Anne received an MBA in Business Management from Loyola College and is also a CPA.

According to Peter Buzy, Paragon's EVP and COO, "with the completion of our recent financing and our new executive team on board, Paragon is positioned to accelerate our growth while continuing to provide outstanding quality service to our world class pharmaceutical, government agency and biotechnology customers."

About Paragon Bioservices, Inc.

Founded in 1990, Paragon Bioservices is a CRO-CMO whose focus is biopharmaceuticalsincluding the production and purification of monoclonal antibodies, recombinant proteins, viral vectors and vaccines.  The company provides research services, process development, and cGMP manufacturing.  Paragon's cGMP space includes microbial and mammalian suites, fill-finish and fully-segregated virus and BSL-3 facilities.

Media Contact

Debbie James
Paragon Bioservices, Inc.
410-975-4050

Logo - http://photos.prnewswire.com/prnh/20141124/160644LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/paragon-announces-management-team-additions-300024982.html

SOURCE Paragon Bioservices, Inc.

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.